BNTX

The trial met its primary endpoint of progression-free survival at an interim analysis, indicating that the drug is effective in treating HER2-positive unresectable or metastatic breast cancer patients who have previously received trastuzumab and a taxane-based chemotherapy.

The collaboration between BioNTech and DualityBio aims to accelerate the development of differentiated ADC therapeutics for solid tumors, and trastuzumab pamirtecan is seen as a potential new treatment option, especially in regions like the United States and the European Union, where breast cancer incidence is high.

This is the first positive late-stage data readout achieved in the collaboration between the two companies initiated in April 2023, reinforcing BioNTech's strategic focus on developing a robust oncology pipeline.